The higher dose of 0.14 mol/kg had even greater effects, with less than 25% of radioactivity remaining in the stomach after 15 minutes
GHSR agonists (ipamorelin) and GHRH analogs (CJC-1295) act through synergistic pituitary signaling pathways, producing GH release 2-5x greater than either peptide alone
Semaglutide storage in context: comparing GLP-1 receptor agonist stability Semaglutide is not the only GLP-1 receptor agonist in widespread use, and comparing storage requirements across this drug class provides useful perspective
Selective Potency: Unlike older secretagogues, Ipamorelin is highly selective
Selective GH Release Ipamorelin Ipamorelin produces GH release without significant cortisol, prolactin, or ACTH elevation, making it the cleanest GHS-R1a agonist for isolated GH stimulation research Combined GHRH/GHRP Protocols Ipamorelin Ipamorelin's selectivity makes it the preferred GHRP partner for combination with GHRH analogs like CJC-1295 (No DAC) or sermorelin, capturing synergistic GH release without adding hormonal side effects Appetite Stimulation and Cachexia Research GHRP-6 GHRP-6 produces significant appetite stimulation through hypothalamic ghrelin signaling, making it valuable in research on wasting, cachexia, and conditions requiring increased caloric intake Long-Term GH Optimization Ipamorelin The absence of cortisol elevation and appetite disruption makes ipamorelin better suited for sustained protocols where repeated dosing over weeks or months is expected Maximum Acute GH Release GHRP-6 GHRP-6 produces higher peak GH levels than ipamorelin at comparable doses, making it preferred when the largest possible acute GH pulse is the primary research endpoint Evening or Bedtime Dosing Ipamorelin Ipamorelin does not stimulate appetite or elevate cortisol, avoiding sleep disruption from hunger and the cortisol spike that could interfere with natural nighttime GH release patterns Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
